Glucocorticoids may compromise the effect of gefitinib in non-small cell lung cancer.

about

Metapristone (RU486 metabolite) suppresses NSCLC by targeting EGFR-mediated PI3K/AKT pathway.

P2860

Q43987893-0715F523-E7D1-4893-B165-0D386B36028F

P2860

Glucocorticoids may compromise the effect of gefitinib in non-small cell lung cancer.

Item

http://www.wikidata.org/entity/Q37699154

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Glucocorticoids may compromise the effect of gefitinib in non-small cell lung cancer.

@en

Glucocorticoids may compromise the effect of gefitinib in non-small cell lung cancer.

@nl

type

Item

label

Glucocorticoids may compromise the effect of gefitinib in non-small cell lung cancer.

@en

Glucocorticoids may compromise the effect of gefitinib in non-small cell lung cancer.

@nl

prefLabel

Glucocorticoids may compromise the effect of gefitinib in non-small cell lung cancer.

@en

Glucocorticoids may compromise the effect of gefitinib in non-small cell lung cancer.

@nl

P1476

Glucocorticoids may compromise the effect of gefitinib in non-small cell lung cancer.

@en

P2093

Chih-Cheng Hsu

http://www.w3.org/2001/XMLSchema#string

Ching-Ping Tseng

http://www.w3.org/2001/XMLSchema#string

Chun-Chun Cheng

http://www.w3.org/2001/XMLSchema#string

Han-Chin Cheng

http://www.w3.org/2001/XMLSchema#string

Hsian-Yu Wang

http://www.w3.org/2001/XMLSchema#string

Hsing-Yi Chang

http://www.w3.org/2001/XMLSchema#string

Hui-Ju Tsai

http://www.w3.org/2001/XMLSchema#string

John T-A Hsu

http://www.w3.org/2001/XMLSchema#string

Min-Wu Chao

http://www.w3.org/2001/XMLSchema#string

Shih-Jen Liu

http://www.w3.org/2001/XMLSchema#string

P2860

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

Glucocorticoid receptors in lung cancer: new perspectives

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

Dexamethasone reduces sensitivity to cisplatin by blunting p53-dependent cellular senescence in non-small cell lung cancer

Systematic review of the clinical effect of glucocorticoids on nonhematologic malignancy.

Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors

P304

85917-85928

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.13185

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-11-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27835586

http://www.w3.org/2001/XMLSchema#string

P932

5349885

http://www.w3.org/2001/XMLSchema#string

Glucocorticoids may compromise the effect of gefitinib in non-small cell lung cancer.

about

P2860

P2860

Glucocorticoids may compromise the effect of gefitinib in non-small cell lung cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932